[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367447-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367447-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dual-nuclide-biodistribution-and-therapeutic-evaluation-of-a-novel-antibody-based-radiopharmaceutical-in-anaplastic-thyroid-cancer-xenografts","Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts","","Anaplastic thyroid cancer (ATC) is highly lethal, and identifying effective therapies remains critical. This study evaluates CD44v6 as a molecular radiotherapy target by assessing CD44v6 expression in 39 ATC patient samples using IHC. Biodistribution and dosimetry of iodine-125 (125I)/lutetium-177 (177Lu)-labeled UU-40, a CD44v6-specific antibody, are followed by in vivo efficacy in two ATC xenograft models with different target expression levels, using SPECT imaging. 177Lu-labeled UU-40 shows favorable biodistribution, specificity, and strong tumor-targeted therapeutic effects including complete response after a single 177Lu-optimized dose.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dual-nuclide-biodistribution-and-therapeutic-evaluation-of-a-novel-antibody-based-radiopharmaceutical-in-anaplastic-thyroid-cancer-xenografts/367447/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dual-nuclide-biodistribution-and-therapeutic-evaluation-of-a-novel-antibody-based-radiopharmaceutical-in-anaplastic-thyroid-cancer-xenografts/367447.png","ImageObject",300,407,{"name":42,"@type":43},"Sophia Brooks","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic target is investigated for ATC molecular radiotherapy?","Question",{"text":63,"@type":64},"The study investigates the cell surface antigen CD44v6, which is overexpressed in several cancers and is evaluated as a target for radiotherapy in anaplastic thyroid cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is CD44v6 expression measured in the study?",{"text":68,"@type":64},"CD44v6 expression is evaluated using immunohistochemistry (IHC) on 39 patient samples with ATC.",{"name":70,"@type":61,"acceptedAnswer":71},"What radiolabeled antibody is tested and how do the two radionuclides compare?",{"text":72,"@type":64},"A CD44v6-specific antibody, UU-40, is labeled with either iodine-125 (125I) or lutetium-177 (177Lu). The biodistribution favors 177Lu-labeled UU-40 over the 125I-labeled antibody and confirms in vivo specificity for both conjugates.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367447,1790229921,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts  \nAnja Charlotte Lundgren Mortensen1,2, Hanna Berglund2, Preeti Jha2,3, Adam Stenman4,5, Ram Kumar Selvaraju6, Hans Lundqvist2, Camilla Hofstrm7, Helena Persson7, C. Christofer Juhlin4,5, Jan Zedenius1,8, Fredrik Y. Frejd2, and Marika Nestor2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Anaplastic thyroid cancer (ATC) is a rare but severe form of thyroid cancer responsible for approximately 50% of thyroid cancer deaths. Consequently, the identification of innovative therapies remains crucial for the effective treatment of ATC. Molecular radiotherapy is a rapidly growing field within oncology, and the cell surface antigen CD44v6, which is overexpressed in several cancers, is a plausible target for molecular radiotherapy of ATC. IHC of 39 patient samples with ATC was evaluated for CD44v6 expression. Biodistribution and dosimetry of iodine-125 (125I)–/lutetium-177 (177Lu)–labeled UU-40, a CD44v6-specific antibody, followed by in vivo efficacy in two ATC xenograft models with varying target expression levels (ACT-1 and BHT- 101), accompanied by single-photon emission computed tomography (SPECT) imaging, evaluated radiolabeled UU-40 for therapeutic efficiency in ATC xenografts. The IHC revealed\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | CD44v6 immunoreactivity in 46% of patient samples with ATC. The biodistribution favored 177Lu-labeled UU-40 over the 125I-labeled antibody and confirmed the in vivo specificity of both radioconjugates. The in vivo efficacy and accompanied SPECT imaging of a moderate CD44v6-expressing xenograft model (BHT-101) verified the tumor specificity, as well as the targetspecific effect of 177Lu-labeled UU-40 on tumor growth and survival. A 100% complete response rate was demonstrated as a result of therapy using a single dose of 16 MBq 177Lu-labeled UU- 40 in a high CD44v6-expressing xenograft model (ACT-1), and SPECT imaging revealed excellent tumor uptake of the radioconjugate at 14 days after injection. This study verifies the expression of CD44v6 in ATC and strengthens the superiority and promise of 177Lu-labeled UU-40 over 131I-labeled UU-40 for antibody-based molecular radiotherapy of CD44v6-positive ATC. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nAnaplastic thyroid cancer (ATC), constituting merely 3% to 5% of all thyroid cancer cases, is a rare yet highly lethal tumor form, accountable for approximately 50% of thyroid cancer–related deaths (1, 2) . Contrary to most thyroid cancers, in which favorable outcomes prevail, the median survival of ATC is less than 6 months after diagnosis, whereas 5-year overall survival rates are \u003C10%(3) . The aggressive nature of the primary tumor, propensity for metastasis, and resistance to conventional chemotherapies pose significant  \n1Department","cbCaikPBw2067t5K","https://ap.wps.com/l/cbCaikPBw2067t5K","pdf",14975715,"English","# Introduction\n## Background on ATC and therapeutic need\n## Molecular radiotherapy and CD44v6 targeting\n# Materials and Methods\n## CD44v6 expression assessment\n## Radiolabeled UU-40 biodistribution and dosimetry\n## Xenograft models and SPECT imaging\n# Results\n## CD44v6 expression in patient samples\n## Biodistribution comparison of 177Lu vs 125I\n## Tumor uptake, tumor specificity, and therapeutic efficacy\n# Conclusion\n## Promise of 177Lu-labeled UU-40 for CD44v6-positive ATC","[{\"question\":\"What therapeutic target is investigated for ATC molecular radiotherapy?\",\"answer\":\"The study investigates the cell surface antigen CD44v6, which is overexpressed in several cancers and is evaluated as a target for radiotherapy in anaplastic thyroid cancer.\"},{\"question\":\"How is CD44v6 expression measured in the study?\",\"answer\":\"CD44v6 expression is evaluated using immunohistochemistry (IHC) on 39 patient samples with ATC.\"},{\"question\":\"What radiolabeled antibody is tested and how do the two radionuclides compare?\",\"answer\":\"A CD44v6-specific antibody, UU-40, is labeled with either iodine-125 (125I) or lutetium-177 (177Lu). The biodistribution favors 177Lu-labeled UU-40 over the 125I-labeled antibody and confirms in vivo specificity for both conjugates.\"}]","Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts | PDF",1790170826,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f7e7aaf29c47cbd27240cd92302bf99.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b10e82303340dbeb6ef0d1a54d5eff2e.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b51cbdeccac1f2a82dc7a5afadc0e447.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbb1cb07f17f9b6d69d6b2a17ffb32ab.webp",980,1311]